Share
A study presented at ENDO 2022 in Atlanta this past summer suggests that active testosterone therapy for transgender men may negatively impact IVF outcomes. Research presented by Amanda Schwartz, MD, a reproductive endocrinology and infertility fellow at the University of Michigan, found that female mice currently receiving testosterone had fewer and less developed eggs retrieved....
Share
Women who are longer-term survivors of metastatic breast cancer may have a worse survival rate if they have diabetes and poorly controlled blood sugar levels, according to a study presented at ENDO 2022. The authors of the study point out that a well-established relationship between diabetes and breast cancer exists, but it’s still unclear how...
Share
Researchers from the University of Basel and University Hospital Basel have identified how the sensory perception of a meal generates a signal to the pancreas to ramp up insulin production: inflammatory factor interleukin 1 beta (IL1β), which is also involved in the immune response to pathogens or in tissue damage. The team reported their findings...
Share
ENDO 2022 saw the presentation of positive clinical data from the open-label extensions (OLEs) of two of the Phase 3 trials of oral octreotide for patients with acromegaly. Amryt is marketing the drug as Mycapssa. Data presented in a late-breaking poster presentation of the 2nd year of the OLE of OPTIMAL (NCT03252353), a randomized, double-blind...
Share
Last summer, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. The FDA granted approval for insulin glargine-yfgn to Mylan Pharmaceuticals Inc., who is marketing the product as Semglee. Semglee...
Share
Physicians may be able to determine if menopause-related bone loss is already in progress or about to begin by measuring the level of a hormone that declines as women approach their final menstrual period, according to a study recently published in Journal of Bone and Mineral Research. The findings could help physicians determine when, and...
Share
Positive results from the Phase III LINC 4 study have confirmed the efficacy and safety of osilodrostat, an oral therapy for patients with Cushing’s disease. The results were published in The Journal of Clinical Endocrinology & Metabolism. Recordati Rare Diseases is marketing the drug as ISTURISA®. The LINC 4 study augments the efficacy and safety...
Share
A review recently published in Endocrinology offers some new insights on how maternal obesity-associated gestational diabetes (GDM) affects the reproductive health of offspring, discussing possible mechanisms, the latest perceptions, and highlighting areas that need further investigation. The review, by Niharika Sinha, PhD; Gretchen Lydia Walker; and Aritro Sen, PhD, all of Michigan State University in...
